Gilead Implements Contract Pharmacy Integrity Initiative for Branded Hepatitis C Products

Gilead Implements Contract Pharmacy Integrity Initiative for Branded Hepatitis C Products

Gilead Implements Contract Pharmacy Integrity Initiative for Branded Hepatitis C Products

Foster City, California, March 15, 2022 – Gilead Sciences, Inc. (Nasdaq: GILD) announced today that the company will launch a contract pharmacy integrity program that aims to improve transparency in the federal drug pricing program 340B and address duplicate discounts and diversion.

Gilead recognizes the important role of the 340B program in providing medicines to low-income people. The 340B program has grown rapidly in recent years, and a well-documented lack of program oversight has raised concerns among stakeholders about the integrity and sustainability of the program. Over time, Gilead has seen duplicate discounts and diversion of its hepatitis C products distributed through contract pharmacies more frequently. This means that multiple discounts have been improperly applied to the same single bottle of Gilead medicine and / or discounts are being requested on bottles dispensed to people who are not patients of an entity covered by 340B.

As part of the integrity program, Gilead requires entities covered by 340B to provide data on the level of complaints per unit of Gilead products for hepatitis C, Epclusa® (sofosbuvir / velpatasvir), Harvoni® (ledipasvir / sofosbuvir), Sovaldi ® (sofosbuvir) and Vosevi® (sofosbuvir / velpatasvir / voxilaprevir) released from contract pharmacies starting May 2, 2022. This integrity program does not apply to authorized generics of Epclusa® and Harvoni® offered by our subsidiary, Asegua Therapeutics. Sharing claims level data is a necessary step towards greater transparency in the 340B program and will help Gilead address duplicate discounts and inappropriate deviations, while strengthening the integrity and sustainability of the program. The data on the level of complaints requested is similar to the data Gilead receives from other buyers and payers; the data demand is tailored to minimize burdens for covered entities, while mitigating duplicate discounts and diversion problems.

We have sent a letter with further information on the implementation of the program directly to interested entities which can be found here. We look forward to working closely with covered entities to provide access to our medicines to all who could benefit, in a transparent and sustainable way.

United States Prescribing Information for EPCLUSA, HARVONI, SOVALDI, and VOSEVI, including BOXED WARNINGSare available at www.gilead.com.

About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved medical innovations for more than three decades with the goal of creating a healthier world for all people. The company is committed to promoting innovative drugs to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries around the world, headquartered in Foster City, California.

For more information about Gilead, visit the company’s website at www.gilead.com, follow Gilead on Twitter (@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650- 574-3000.

Leave a Comment

Your email address will not be published.